Physician profile
Timothy Swartz
NPI 1851393797
$5,619.66
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,574 · 2020: $1,749 · 2021: $1,995 · 2022: $258 · 2024: $44.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $44.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $44.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $893.05 | 2019-2022 | |
| Janssen Biotech, INC. | $734.82 | 2019-2022 | |
| Amgen INC. | $681.69 | 2019-2022 | |
| Pfizer INC. | $493.24 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $464.07 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $401.23 | 2019-2021 | |
| Ucb, INC. | $301.21 | 2019-2022 | |
| Celgene Corporation | $206.90 | 2019 | |
| Eisai INC. | $174.90 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $163.48 | 2019-2021 | |
| Glaxosmithkline, LLC. | $140.39 | 2019-2022 | |
| Almatica Pharma LLC | $116.97 | 2020-2021 | |
| Genentech USA, INC. | $116.17 | 2019 | |
| Radius Health, INC. | $102.77 | 2019-2022 | |
| Lilly USA, LLC | $102.73 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $70.28 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.21 | 2019-2021 | |
| Nevro Corp. | $50.25 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $47.70 | 2021 | |
| Vertical Pharmaceuticals, LLC | $45.14 | 2019 | |
| Abbott Laboratories | $44.28 | 2024 | Proclaim |
| Tersera Therapeutics LLC | $38.44 | 2019 | |
| Antares Pharma, INC. | $36.01 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $34.30 | 2020-2021 | |
| Daiichi Sankyo INC. | $26.24 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.32 | 2021 | |
| Boston Scientific Corporation | $13.95 | 2020 | |
| Ibsa Pharma INC. | $13.49 | 2021 | |
| Bioventus LLC | $13.13 | 2019 | |
| Depuy Synthes Sales INC. | $12.26 | 2020 | |
| Arbor Pharmaceuticals, INC. | $11.04 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Swartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.